Semnur Pharmaceuticals, Inc. (SMNR) reported a $3.633 million net loss for the quarter ended September 30, 2026, versus $152.594 million a year earlier; 2025 general and administrative expense included $140.163 million of stock-based compensation. For the first nine months, operating loss was $12.377 million and operating cash use was $7.030 million.
At September 30, Semnur had $54,000 cash, $35.315 million in liabilities and a $24.036 million related-party loan payable to its parent, Scilex. Management said Semnur depends on Scilex for services and funding pending external financing, and concluded conditions raise substantial doubt about its ability to continue as a going concern for one year after the statements were issued. Certain Q1 2026 note installments were not paid; Semnur reported no notice of default and expected payment by year-end.
A binding term sheet contemplates iHolding Group LLP purchasing $100.0 million of new common stock at an expected $10.00 per share; no definitive agreement had been executed as of September 30. Semnur terminated its $20.0 million PIPE and $100.0 million Biconomy purchase agreements on April 20, 2026. It is developing SP-102 and initiated its second Phase 3 study in September 2025.
Semnur Pharmaceuticals, Inc., a late-stage biopharmaceutical company developing non-opioid pain product SP-102/SEMDEXA, reports sharply higher operating expenses and losses for the quarter and six months ended June 30, 2026. Research and development and general and administrative spending rose significantly as the company advances Phase 3 development.
For the six-month period, the company recorded a net loss of $8.9 million, compared with $1.7 million a year earlier, driven by higher R&D, stock-based compensation and corporate costs. Cash and cash equivalents were only $39 thousand against total liabilities of $31.6 million, resulting in a stockholders’ deficit of $29.7 million and a heavy reliance on related-party funding from parent Scilex.
Management explicitly states that recurring losses, minimal cash, dependence on external financing and Scilex support, and the need to fund continued development of SP-102 raise substantial doubt about the ability to continue as a going concern. Previously announced equity financings, including a $20 million PIPE and a $100 million Bitcoin-funded purchase agreement, were terminated. After quarter end, the company signed a binding term sheet with iHolding Group LLP for a proposed $100 million common stock investment, but closing is subject to numerous conditions and may not occur.
Semnur Pharmaceuticals entered into a binding term sheet with iHolding Group LLP for a proposed $100,000,000 equity investment. iHolding is expected to buy newly issued Semnur common shares at $10.00 per share, or about 10,000,000 shares, pending detailed agreements and approvals.
The companies expect proceeds, if the deal closes, to support Semnur’s pipeline, including the ongoing Phase 3 program for SEMDEXA (SP-102), and broader growth initiatives. The transaction is subject to due diligence, definitive agreements, board, stockholder and regulatory approvals, and may not be completed.
Scilex Holding Company filed an amended Schedule 13D showing continued majority ownership of Semnur Pharmaceuticals after a stock dividend. Scilex is deemed to beneficially own 181,520,112 shares of Semnur common stock, representing 78.85% of the outstanding class based on 230,209,142 shares.
Including 5,423,606 shares of Series A Preferred Stock that vote with common stock, Scilex’s aggregate holdings represent 79.34% of total voting power. On June 15, 2026, Scilex and its subsidiaries distributed 7,034,737 Semnur common shares as a dividend to Scilex stockholders and other eligible equity holders of record as of June 1, 2026.
Scilex Holding Co, a major holder of Semnur Pharmaceuticals, Inc., reported a previously announced stock dividend of 13,972,900 shares of Semnur common stock distributed to its own common shareholders and certain warrant and convertible note holders as of a June 1, 2026 record date.
The filing notes that 6,938,163 of these dividend shares are being held in abeyance for additional participating warrant and note holders, to be distributed if and when those instruments are exercised or converted, with a separate Form 4 to be filed at that time. The report also shows a J-code restructuring entry for 7,034,737 Semnur common shares at a stated price of $0.0000 per share and updated direct and indirect ownership positions, including shares held through Scilex, Inc. and Scilex Bio, Inc.
Semnur Pharmaceuticals, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 25, 2026. Stockholders representing 5,423,606 shares of Series A preferred stock and 200,307,471 shares of common stock, or about 87% of common shares outstanding as of April 28, 2026, were present virtually or by proxy.
Stockholders elected Jay Chun, M.D., Ph.D. as a Class I director to serve until the 2029 annual meeting. They also ratified Pipara & Co LLP as independent registered public accounting firm for the year ending December 31, 2026, and approved both the 2025 Equity Incentive Plan and the 2025 Employee Stock Purchase Plan.
Semnur Pharmaceuticals filed a prospectus supplement and attached Form 10-Q updating its S-1 registration. The supplement registers up to 203,737,349 shares for resale by selling securityholders and up to 7,432,122 shares issuable upon exercise of warrants, and registers 510,000 private warrants for resale.
The Form 10-Q shows $0.1M cash at March 31, 2026, a three-month net loss of $4.6M, accumulated deficit of $280.4M, and 230,209,142 shares outstanding as of April 25, 2026. Management discloses substantial doubt about going concern and dependence on Scilex for funding.
Semnur Pharmaceuticals, Inc. is registering the resale of up to 203,737,349 shares of Common Stock, the registration of up to 7,432,122 shares issuable upon exercise of warrants and up to 510,000 warrants for resale and exercise as described herein, to be offered from time to time by selling securityholders.
The company will receive proceeds only from cash exercises of the Warrants and not from resales by the selling securityholders. The prospectus discloses that Semnur completed a business combination and domestication on September 22, 2025, trades on the OTC Pink as SMNR and SMNRW, and reported last sale prices on May 15, 2026 of $5.99 per share and $0.03 per warrant. The filing also discloses substantial net losses, an accumulated deficit of $275.8 million as of December 31, 2025 and cash and cash equivalents of $20 thousand as of December 31, 2025, and notes substantial doubt about the company’s ability to continue as a going concern.
Semnur Pharmaceuticals, Inc. reports a larger quarterly loss and severe liquidity pressure in its latest period. For the three months ended March 31, 2026, the company recorded a net loss of $4.6 million, up from $0.7 million a year earlier, as research and development and general and administrative expenses increased to $4.6 million in total.
Semnur ended the quarter with only $0.1 million in cash and cash equivalents and total assets of $2.0 million, against total liabilities of $27.3 million, resulting in a stockholders’ deficit of $25.3 million. Operating activities used $2.7 million of cash, which was offset by $2.8 million of net financing inflows, primarily related party loans and partial repayment of promissory notes.
The company terminated both a planned $20.0 million PIPE equity financing and a proposed $100.0 million Bitcoin-funded share purchase agreement in April 2026, leaving it reliant on Scilex Holding Company for services and funding while it advances its lead late-stage pain candidate SP-102. Management states that recurring losses, minimal cash, dependence on Scilex and the need for additional financing raise substantial doubt about Semnur’s ability to continue as a going concern.